The biological properties of therapeutic peptides, such as their pharmacokinetics and pharmacodynamics, are correlated with their structure and aggregation properties. Herein, we studied the aggregation properties of a therapeutic peptide (CIGB-814), currently in phase 2 clinical trial, for the treatment of rheumatoid arthritis over a wide range of concentrations (μM–mM). We applied spectroscopic techniques (fluorescence, circular dichro- ism, resonance, and dynamic light scattering), atomic force microscopy, and molecular dynamics simulations to determine the aggregation mechanism of CIGB-814. We found that the hierarchical aggregation of CIGB-814 at micromolar concentrations was initiated by the formation of peptide oligomers. Subsequently, the peptide oligomers trigger the nucleation and growth of peptide nanostructures (cac = 123 μM), ultimately leading to the fibrillization of CIGB-814 (cac’ = 508 μM). These results pave the way for a deeper understanding of the CIGB-814 therapeutic activity and may give important insights on its pharmacokinetics.
Cimino, R., Savioli, M., Carrante, N.f., Placidi, E., Garay-Perez, H., López-Abad, M., et al. (2022). Aggregation properties of a therapeutic peptide for rheumatoid arthritis: a spectroscopic and molecular dynamics study. CHEMPHYSMATER, 1, 62-70 [10.1016/j.chphma.2021.09.007].
Aggregation properties of a therapeutic peptide for rheumatoid arthritis: a spectroscopic and molecular dynamics study
Gatto, EmanuelaMembro del Collaboration Group
;Cavalieri, FrancescaMembro del Collaboration Group
;Bocchinfuso, GianfrancoMembro del Collaboration Group
;Venanzi, Mariano
Writing – Original Draft Preparation
2022-01-01
Abstract
The biological properties of therapeutic peptides, such as their pharmacokinetics and pharmacodynamics, are correlated with their structure and aggregation properties. Herein, we studied the aggregation properties of a therapeutic peptide (CIGB-814), currently in phase 2 clinical trial, for the treatment of rheumatoid arthritis over a wide range of concentrations (μM–mM). We applied spectroscopic techniques (fluorescence, circular dichro- ism, resonance, and dynamic light scattering), atomic force microscopy, and molecular dynamics simulations to determine the aggregation mechanism of CIGB-814. We found that the hierarchical aggregation of CIGB-814 at micromolar concentrations was initiated by the formation of peptide oligomers. Subsequently, the peptide oligomers trigger the nucleation and growth of peptide nanostructures (cac = 123 μM), ultimately leading to the fibrillization of CIGB-814 (cac’ = 508 μM). These results pave the way for a deeper understanding of the CIGB-814 therapeutic activity and may give important insights on its pharmacokinetics.File | Dimensione | Formato | |
---|---|---|---|
CHPHMA7.pdf
accesso aperto
Descrizione: pdf articolo pubblicato
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
4.43 MB
Formato
Adobe PDF
|
4.43 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.